Search research articles
Contact Us
Filters
Showing results (31-40 of 122) with videos related to
Page
of 13
Sort By:
Leukemia Research
|
April 12, 2016
Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin
Carine Robert, Pratik K Nagaria, Nisha Pawar, et al.
Diagnostic Pathology
|
November 2, 2007
Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study
Borislav A Alexiev, Wenle Wang, Yi Ning, et al.
Leukemia Research
|
February 28, 2007
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies
Ivana Gojo, Michael L Tidwell, Jacqueline Greer, et al.
Investigational New Drugs
|
April 4, 2006
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer
Milin R Acharya, Judith E Karp, Edward A Sausville, et al.
Journal of Palliative Medicine
|
May 25, 2017
A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission
M Jennifer Cheng, B Douglas Smith, Christopher S Hourigan, et al.
International Journal of Hematology
|
October 1, 2022
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency
Michael J Hochman, B Douglas Smith, Theodoros Karantanos, et al.
Investigational New Drugs
|
February 28, 2013
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
Ivana Gojo, Alexander Perl, Selina Luger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2004
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab
Judith E Karp, Ivana Gojo, Roberto Pili, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2009
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias
Ken Shiozawa, Takeo Nakanishi, Ming Tan, et al.
Haematologica
|
December 2, 2021
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
Sumithira Vasu, Jessica K Altman, Geoffrey L Uy, et al.
Page
of 13
Search research articles
Search
Showing results (31-40 of 122) with videos related to
Sort By:
Page
of 13
Leukemia Research
|
April 12, 2016
Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin
Carine Robert, Pratik K Nagaria, Nisha Pawar, et al.
Diagnostic Pathology
|
November 2, 2007
Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study
Borislav A Alexiev, Wenle Wang, Yi Ning, et al.
Leukemia Research
|
February 28, 2007
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies
Ivana Gojo, Michael L Tidwell, Jacqueline Greer, et al.
Investigational New Drugs
|
April 4, 2006
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer
Milin R Acharya, Judith E Karp, Edward A Sausville, et al.
Journal of Palliative Medicine
|
May 25, 2017
A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission
M Jennifer Cheng, B Douglas Smith, Christopher S Hourigan, et al.
International Journal of Hematology
|
October 1, 2022
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency
Michael J Hochman, B Douglas Smith, Theodoros Karantanos, et al.
Investigational New Drugs
|
February 28, 2013
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
Ivana Gojo, Alexander Perl, Selina Luger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2004
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab
Judith E Karp, Ivana Gojo, Roberto Pili, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2009
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias
Ken Shiozawa, Takeo Nakanishi, Ming Tan, et al.
Haematologica
|
December 2, 2021
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
Sumithira Vasu, Jessica K Altman, Geoffrey L Uy, et al.
Page
of 13